SCHEMBL4334867

SCHEMBL4334867

NC(=S)NN=Cc1ccc(N2CCN(Cc3ccc(Cl)c(Cl)c3)CC2)cc1Cl

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.51
HTT P42858 6/20 0.51
ALDH1A1 P00352 5/20 0.51
ALOX12 P18054 3/20 0.51
HPGD P15428 2/20 0.51
LMNA P02545 2/20 0.51
MAPK1 P28482 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
TYR P14679 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
MEN1 O00255 4/20 0.41
KMT2A Q03164 4/20 0.41
PTPN7 P35236 1/20 0.41
DRD2 P14416 1/20 0.41
DRD1 P21728 1/20 0.41
DRD4 P21917 1/20 0.41
DRD5 P21918 1/20 0.41
DRD3 P35462 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
POLB P06746 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4334865 1.00 MAPT (0.51) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4324239 0.90 MAPT (0.48) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4324243 0.90 MAPT (0.48) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4331128 0.90 DRD2 (0.48) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4331135 0.90 DRD2 (0.48) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4329336 0.89 ALDH1A1 (0.49) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4329338 0.89 ALDH1A1 (0.49) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4329372 0.88 THRB (0.45) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4329368 0.88 THRB (0.45) MAPTHTTALDH1A1ALOX12HPGD
SCHEMBL4331399 0.88 TYR (0.53) MAPTHTTALDH1A1ALOX12HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-7521062-B2 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) 2009-04-21 US disclosed
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3619/4885HTT 2994/4885ALDH1A1 1459/4885
US-20050069555-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 MAPT 3876/4885HTT 3282/4885ALDH1A1 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.